PatientsVille.com Logo


Asacol Medical Research Studies

Up-to-date List of Asacol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Asacol Medical Research Studies

Rank Status Study
1 Unknown  Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Dietary Supplement: Curcumin;   Drug: 5-aminosalicylic acid
Outcome Measures: The percentage of patients who achieve clinical remission compared between the two study arms.;   Time to response
2 Recruiting The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Condition: Irritable Bowel Syndrome
Interventions: Drug: Mesalamine;   Drug: Placebo
Outcome Measure: Change from baseline in gastrointestinal symptoms and IBS specific quality of life after an 8 week treatment period
3 Recruiting Predicting Response to Standardized Pediatric Colitis Therapy
Condition: Ulcerative Colitis
Interventions: Drug: Mesalamine;   Drug: Prednisone;   Drug: Corticosteroids followed by mesalamine (Pentasa)
Outcome Measures: Corticosteroid free remission (SFR);   Corticosteroid free remission
4 Recruiting Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: MMX Mesalamine/Mesalazine
Outcome Measures: Clinical Response;   Maintenance of Clinical Response;   Clinical and Endoscopic Response;   Changes in Signs and Symptoms of Mild to Moderate Ulcerative Colitis;   Improvement in Mild to Moderate Ulcerative Colitis;   Remission
5 Recruiting Cimzia Versus Mesalamine for Crohn's Recurrence
Condition: Crohn's Disease
Interventions: Drug: Cimzia;   Drug: Mesalamine
Outcome Measures: Clinical recurrence rates of Crohn's disease;   Endoscopic recurrence of Crohn's disease
6 Recruiting Mesalazine Treatment in IBS (The MIBS Study)
Condition: Irritable Bowel Syndrome
Interventions: Drug: Mesalazine;   Drug: Placebo
Outcome Measures: Global Irritable Bowel Syndrome (IBS) symptoms;   Inflammatory mediators;   Effect on immune cells and cytokines in mucosal biopsies;   Levels of calprotectin in faeces;   Change in total IBS symptom severity score (IBS-SSS);   Individual symptom parameters in IBS symptom severity score (IBS-SSS) and the IBS diary;   Exploratory responder variables
7 Recruiting Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis
Condition: Mild to Moderate Ulcerative Colitis
Intervention: Drug: Mesalamine
Outcome Measures: Difference in mean PUCAI score between the groups.;   Treatment success defined as Complete response OR large partial response.
8 Recruiting Mesalazine Effects in Sporadic Colorectal Adenoma Patients
Condition: Sporadic Colorectal Adenoma
Interventions: Drug: Mesalazine;   Drug: Placebo
Outcome Measures: Apoptotic index;   Proliferation index;   Expression of β-catenin signaling pathway
9 Recruiting Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
Condition: Proctitis
Interventions: Drug: Budesonide 2 mg suppository;   Drug: Budesonide 4 mg suppository;   Drug: Mesalazine 1 g suppository;   Drug: Budesonide 2 mg suppository/Mesalazine 1 g suppository
Outcome Measures: Resolution of clinical symptoms;   Rate of clinical and endoscopic remission;   Rate of improvement;   Rate of patients with clinical remission;   Rate of patients with endoscopic remission
10 Recruiting TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
Condition: Active Ulcerative Colitis
Interventions: Drug: Mesalazine - TID 1000 mg;   Drug: Mesalazine - TID 2x 500 mg
Outcome Measures: Rate of clinical remission;   Number of stools per week;   Number of bloody stools per week;   Time to first resolution of clinical symptoms
11 Recruiting Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.
Conditions: Colorectal Cancer;   Diverticular Disease;   Colitis
Intervention: Drug: Mesalazine
Outcome Measures: Molecular analysis of gene expression levels of μ-protocadherin and other related proteins;   Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid
12 Recruiting Targeting Oxidative Stress in Chronic Beryllium Disease
Condition: Chronic Beryllium Disease
Interventions: Drug: Mesalamine;   Drug: Placebo
Outcome Measures: Beryllium lymphocyte proliferation responses (BeLPT);   Th1 cytokines;   Steady-state GSH levels;   HDAC2 levels;   Glucocorticoid receptors;   Lung function
13 Recruiting Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Ulcerative Colitis.
Condition: Ulcerative Colitis
Interventions: Drug: combination 5-aminosalicylic + hydrocortisone / prednisone;   Drug: IV hydrocortisone / PO prednisone
Outcome Measures: percentage of patients who respond to the treatment;   the percentage of patients in need of a rescue medication;   colectomy rate
14 Recruiting Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)
Conditions: Colitis, Ulcerative;   Inflammatory Bowel Diseases
Interventions: Drug: CGMP protein;   Drug: Maximal oral 5ASA
Outcome Measures: Fecal calprotectin reduction;   Clinical Activity Index;   Quality of life;   Endoscopic Mayo score;   Serial fecal calprotectin
15 Recruiting TP05 for the Treatment of Mild to Moderate Active UC
Condition: Acute Ulcerative Colitis
Interventions: Drug: TP05;   Drug: Asacol
Outcome Measures: Clinical and endoscopic remission;   safety;   proportion of patients in remission
16 Recruiting Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Condition: Crohn's Disease
Interventions: Drug: D9421-C capsule 3 mg;   Drug: Mesalazine tablets
Outcome Measures: Clinical efficacy change defined by a score of 180-400 on the Crohn's Disease Activity Index (CDAI) by assessment of the remission after 8-week treatment defined by a CDAI score of ≤150.;   Remission (ie, CDAI score of ≤150) after 2-week treatment;   Remission (ie, CDAI score of ≤150) after 4-week treatment;   Change in CDAI score;   Time to the first remission;   Clinical improvement defined by a remission (ie, CDAI score of ≤150) or a decrease in CDAI score of at least 100 from baseline;   Clinical improvement defined by a remission (ie, CDAI score of ≤150) or a decrease in CDAI score of at least 70 from baseline;   Change in disease specific health-related quality of life (HRQL) as defined by a score of 180-400 on the CDAI by assessment of the Inflammatory Bowel Disease Questionnaire (IBDQ) total score and all sub scores
17 Recruiting Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
Condition: Lymphocytic Colitis
Interventions: Drug: Budesonide;   Drug: Mesalamine;   Other: Placebo
Outcome Measures: Rate of clinical remission;   Proportion of patients with histological improvement
18 Recruiting Evaluation of the Metabolome in Diverticular Disease
Condition: Simple Diverticular Disease
Interventions: Dietary Supplement: VSL#3;   Drug: Rifaximin;   Drug: Mesalazine;   Dietary Supplement: Psyllium
Outcome Measures: identify the metabolome of symptomatic uncomplicated Diverticular Disease (SUDD);   evaluate the symptomatology and metabolome;   evaluate the different metabolomes according to the treatment used;   Evaluate the effects of supplementation with VSL#3 on the metabolome of Diverticular Disease
19 Recruiting Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)
Condition: Ulcerative Colitis
Outcome Measures: Prevalence of "non-persistence" amongst patients prescribed topical mesalamine for UC;   Clinical outcome (remission / relapse) at 12 months grouped by persistence status;   Adherence phenotype details;   Quality-of-life score at 12 months
20 Recruiting Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission
Conditions: Inflammatory Bowel Diseases;   Crohn's Disease;   Gastrointestinal Diseases;   Digestive System Diseases;   Intestinal Diseases
Intervention: Drug: Mesalazine, Tripterygium glycosides
Outcome Measures: Therapeutic effect measured by Crohn's Disease Activity Index (CDAI);   The Side effects of Tripterygium wilfordii (TW);   The change of Crohn's Disease Activity Index (CDAI );   The change of Simple Endoscopic Score for Crohn's Disease(SES-CD);   The change of the Inflammatory Bowel Disease Questionnaire (IBDQ)

These studies may lead to new treatments and are adding insight into Asacol etiology and treatment.

A major focus of Asacol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Asacol